231 related articles for article (PubMed ID: 20531187)
1. The pathology of and controversial aspects of ovarian borderline tumours.
McCluggage WG
Curr Opin Oncol; 2010 Sep; 22(5):462-72. PubMed ID: 20531187
[TBL] [Abstract][Full Text] [Related]
2. Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.
Kane SV; Bharadwaj R; Tongaonkar HB
Indian J Cancer; 1999 Mar; 36(1):18-31. PubMed ID: 10810551
[TBL] [Abstract][Full Text] [Related]
3. Pathology of borderline (low malignant potential) ovarian tumours.
Seidman JD; Ronnett BM; Kurman RJ
Best Pract Res Clin Obstet Gynaecol; 2002 Aug; 16(4):499-512. PubMed ID: 12413931
[TBL] [Abstract][Full Text] [Related]
4. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
5. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
6. Borderline epithelial tumors of the ovary.
Hart WR
Mod Pathol; 2005 Feb; 18 Suppl 2():S33-50. PubMed ID: 15761465
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
[TBL] [Abstract][Full Text] [Related]
8. Serous borderline tumours of the ovary.
Kurman RJ; Seidman JD; Shih IM
Histopathology; 2005 Sep; 47(3):310-5. PubMed ID: 16115232
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
10. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence.
Morice P; Uzan C; Fauvet R; Gouy S; Duvillard P; Darai E
Lancet Oncol; 2012 Mar; 13(3):e103-15. PubMed ID: 22381933
[TBL] [Abstract][Full Text] [Related]
11. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
12. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
13. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
14. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
[TBL] [Abstract][Full Text] [Related]
15. Metastatic serous borderline ovarian tumor in an internal mammary lymph node: a case report and review of the literature.
Chamberlin MD; Eltabbakh GH; Mount SL; Leavitt BJ
Gynecol Oncol; 2001 Jul; 82(1):212-5. PubMed ID: 11426990
[TBL] [Abstract][Full Text] [Related]
16. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
Seidman JD; Kurman RJ
Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
[TBL] [Abstract][Full Text] [Related]
17. [Ovarian tumors of low malignant potential (borderline ovarian tumors)].
Luchian AM; Pricop M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):438-45. PubMed ID: 21870737
[TBL] [Abstract][Full Text] [Related]
18. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
19. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
Vasconcelos I; Darb-Esfahani S; Sehouli J
BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
[TBL] [Abstract][Full Text] [Related]
20. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
Djordjevic B; Malpica A
Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
